- Home
- IONR vs ACHV Comparison
IONR vs ACHV Comparison
Compare IONR & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONR
- ACHV
- Stock Information
- Founded
- IONR 2001
- ACHV N/A
- Country
- IONR Australia
- ACHV Canada
- Employees
- IONR N/A
- ACHV N/A
- Industry
- IONR
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- IONR
- ACHV Health Care
- Exchange
- IONR Nasdaq
- ACHV Nasdaq
- Market Cap
- IONR 319.2M
- ACHV 126.9M
- IPO Year
- IONR N/A
- ACHV N/A
- Fundamental
- Price
- IONR $4.11
- ACHV $3.15
- Analyst Decision
- IONR
- ACHV Strong Buy
- Analyst Count
- IONR 0
- ACHV 5
- Target Price
- IONR N/A
- ACHV $14.80
- AVG Volume (30 Days)
- IONR 25.0K
- ACHV 260.4K
- Earning Date
- IONR 01-01-0001
- ACHV 11-07-2024
- Dividend Yield
- IONR N/A
- ACHV N/A
- EPS Growth
- IONR N/A
- ACHV N/A
- EPS
- IONR N/A
- ACHV N/A
- Revenue
- IONR N/A
- ACHV N/A
- Revenue This Year
- IONR N/A
- ACHV N/A
- Revenue Next Year
- IONR N/A
- ACHV N/A
- P/E Ratio
- IONR N/A
- ACHV N/A
- Revenue Growth
- IONR N/A
- ACHV N/A
- 52 Week Low
- IONR $2.90
- ACHV $3.12
- 52 Week High
- IONR $9.35
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- IONR 42.24
- ACHV 26.85
- Support Level
- IONR $3.71
- ACHV $3.50
- Resistance Level
- IONR $4.58
- ACHV $3.86
- Average True Range (ATR)
- IONR 0.34
- ACHV 0.20
- MACD
- IONR 0.07
- ACHV -0.03
- Stochastic Oscillator
- IONR 51.04
- ACHV 4.05
About IONR ioneer Ltd
Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.